IBM scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale and could enable physicians to detect diseases such as cancer before symptoms appear.
As reported today in the journal Nature Nanotechnology, the IBM team’s results show size-based separation of bioparticles down to 20 nanometers (nm) in diameter, a scale that gives access to important particles such as DNA, viruses and exosomes. Once separated, these particles can potentially be analyzed by physicians to reveal signs of disease even before patients experience any physical symptoms and when the outcome from treatment is most positive. Until now, the smallest bioparticle that could be separated by size with on-chip technologies was about 50 times or larger, for example, separation of circulating tumor cells from other biological components.
IBM is collaborating with a team from the Icahn School of Medicine at Mount Sinai to continue development of this lab-on-a-chip technology and plans to test it on prostate cancer, the most common cancer in men in the U.S.
In the era of precision medicine, exosomes are increasingly being viewed as useful biomarkers for the diagnosis and prognosis of malignant tumors. Exosomes are released in easily accessible bodily fluids such as blood, saliva or urine. They represent a precious biomedical tool as they can be used in the context of less invasive liquid biopsies to reveal the origin and nature of a cancer.
The IBM team targeted exosomes with their device as existing technologies face challenges for separating and purifying exosomes in liquid biopsies. Exosomes range in size from 20-140nm and contain information about the health of the originating cell that they are shed from. A determination of the size, surface proteins and nucleic acid cargo carried by exosomes can give essential information about the presence and state of developing cancer and other diseases.
exosomes of size 100 nm and larger could be separated from smaller exosomes, and that separation can take place in spite of diffusion, a hallmark of particle dynamics at these small scales. With Mt. Sinai, the team plans to confirm their device is able to pick up exosomes with cancer-specific biomarkers from patient liquid biopsies.
“The ability to sort and enrich biomarkers at the nanoscale in chip-based technologies opens the door to understanding diseases such as cancer as well as viruses like the flu or Zika,” said Gustavo Stolovitzky, Program Director of Translational Systems Biology and Nanobiotechnology at IBM Research. “Our lab-on-a-chip device could offer a simple, noninvasive and affordable option to potentially detect and monitor a disease even at its earliest stages, long before physical symptoms manifest. This extra amount of time allows physicians to make more informed decisions and when the prognosis for treatment options is most positive.”
The Latest on: IBM Lab-on-a-Chip
via Google News
The Latest on: IBM Lab-on-a-Chip
- Technology Bulletinon March 30, 2021 at 5:00 pm
Better living through biomedical polymers At The Polymer Technology Group, Inc., surface-modifying end groups (SMEs), chemically bonded to a base ...
- Archer Materials strengthens graphene-based biochip nanofabrication capabilitieson March 22, 2021 at 2:34 am
Key biosensor components of Archer’s lab-on-a-chip device have been miniaturised to nano-size chip formats which are a requirement for successful biochip development. The biochip end-use is ...
- The global high-throughput screening market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5%on March 8, 2021 at 3:12 am
Label-free Technology segment accounted for the highest CAGR Based on technology , the high-throughput screeningmarket is segmented into cell-based assays, lab-on-a-chip technology, and label-free ...
- Working togetheron April 15, 2019 at 5:11 am
“For lab-on-a-chip applications, this mechanism can be ... industries of the future,” explains Diamond. “For example, IBM now has a strong environmental stream and is involved in developing ...
- 2000 Subject index — Volume 18on September 8, 2018 at 5:06 pm
367 L Lab-on-a-chip devices, “015 patent,” 1229 Laboratory test patents, physician proposals, 707,1021 Lambda repressor, protein dimerization, 815,847 Laminin, fibrin matrices incorporation of ...
- Topic: jama softwareon November 22, 2017 at 9:10 am
2016 IBM this week announced that its scientists have developed a new lab-on-a-chip technology that can separate biological particles at the nano scale to help physicians detect things like cancer.
- Paula E. Milleron May 30, 2017 at 6:47 am
The current extraterritorial reach of U.S. trade secret law may seem ironic given trade secret law’s “local” roots. In the United States, common law trade … ...
- New Nanobiotech Chip May Help Doctors Discover Cancer Earlieron November 22, 2016 at 8:19 am
Which is something IBM took quite literally. IBM has partnered with the Icahn School of Medicine at Mount Sinai to develop lab-on-a-chip technology, which will allow previously lab-based tests to ...
- Can Nanotechnology Save Lives?on June 27, 2010 at 11:00 pm
Already, IBM uses self-assembly techniques to produce ... the thing Whitesides is now holding in his hand, a so-called lab on a chip no bigger than a postage stamp, which is designed to diagnose ...
via Bing News